免疫检查点抑制剂诱发银屑病的全身治疗:基于推断的指导
本文针对免疫检查点抑制剂(ICI)诱发的银屑病(ICI-Ps),由15名国际多学科专家采用Delphi流程确定临床关注点,并通过系统综述和推断方法学得出结论。专家支持全身治疗可用于ICI-Ps而不会明显降低ICI疗效,通常无需中断ICI治疗,非甾体全身治疗优于全身糖皮质激素。
要点
- 全身治疗可用于ICI-Ps,无明显ICI疗效损失。
- 通常无需中断ICI治疗。
- 优先选择非甾体全身治疗而非全身糖皮质激素。
核心结论
- 尽管无直接证据,支持全身治疗可用于ICI-Ps而不明显损失ICI疗效。
- 通常不需要中断ICI治疗。
- 治疗银屑病时,若有条件,非甾体全身治疗优于全身糖皮质激素。
研究设计与样本
- 15名国际皮肤科、肿瘤科、免疫科和风湿科专家组成多学科小组。
- 采用Delphi流程确定与ICI-Ps全身治疗相关的临床关注点。
- 系统综述文献,辅以支持基于推断方法学的证据。
- 专家小组使用概率量表评定结论强度。
主要发现
- 全身治疗可能用于治疗ICI-Ps而无明显ICI疗效损失。
- 通常不必中断ICI治疗。
- 非甾体全身治疗优先于全身糖皮质激素。
临床怎么用
- 可与患者讨论使用全身治疗的风险与获益。
- 优先选用非甾体全身治疗。
- 通常无需中断ICI治疗。
局限性
- 无直接高级别证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors (ICIs) are increasingly used to treat various cancers. Their use may result in immune-related adverse events, including psoriasis. When managing psoriasis, induced or exacerbated by an ICI, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis (saPs) and the potential impact on ICI efficacy. No direct, high-level evidence exists to address these concerns. OBJECTIVE: To address clinically relevant questions regarding the management of ICI-mediated psoriasis (ICI-Ps) with saPs. METHODS: We convened a multidisciplinary panel of 15 international specialists in dermatology, oncology, immunology, and rheumatology. A Delphi process defined clinical concerns related to the systemic treatment of ICI-Ps, focusing on the potential of saPs to impact ICI effectiveness. The saPs considered included biologics targeting tumour necrosis factor, interleukin (IL)-17, IL-12/23 and IL-23, traditional systemic therapies (cyclosporine, methotrexate), small molecules targeting phosphodiesterase-4 or tyrosine kinase 2, systemic retinoids (acitretin), and systemic corticosteroids. A systematic review of the literature was supplemented with evidence supporting an inference-based methodology to derive conclusions on the use of systemic therapies in patients with ICI-Ps. The specialist panel rated the strength of the conclusions using a probabilistic scale. RESULTS: After reviewing the totality of direct and indirect evidence, we drafted inference-based conclusions and ascribed a level of support, focusing on the potential impact of saPs on ICI efficacy. This work provides a structured framework informing healthcare professional and patient discussions on the risks and benefits of using saPs in patients with cancer who experience ICI-Ps. CONCLUSIONS: Although there is no direct evidence, we support the following conclusions: saPs may be used to treat ICI-Ps without an appreciable loss of ICI effectiveness. Generally, it is not necessary to interrupt ICI therapy. When available, non-steroid saPs are preferred over systemic corticosteroids for the treatment of psoriasis.
引用
- Papp KA, Puig L, Beecker J, et al. Systemic treatment of immune checkpoint inhibitor-induced psoriasis: Inference-based guidance. J Eur Acad Dermatol Venereol. 2025. PMID: 40685883. doi:10.1111/jdv.20809
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。